Idiopathic pulmonary fibrosis trials in China

In China 25 Also abroad 111

25 trials · From ClinicalTrials.gov, checked 11 November 2026. Ask the study team whether a trial fits you.

Phase 2Enrolling by invitation
A Phase Ⅱa Study of ND-003 Tablets in Patients With Idiopathic Pulmonary Fibrosis
Where
Guangzhou
Age
40 years and over
People
10
Run by
Shenzhen NewDEL Biotech, Co., Ltd
See details and how to joinNCT07929948
Phase 2Not yet taking people in China
A Phase 2 Study of HB0056 in Patients With Idiopathic Pulmonary Fibrosis
Where
Changsha, Shanghai
Age
40 years to 80 years
People
75
Run by
Shanghai Huaota Biopharmaceutical Co., Ltd.
See details and how to joinNCT07909655
Phase 3Not yet taking people in China
Long-term Extension Study to Evaluate Safety and Tolerability of Admilparant in Participants With Pulmonary Fibrosis
Where
Beijing, Changsha, Chengdu, Guangzhou, Hangzhou, Hefei, Hohhot, Lanzhou, Nanjing, Ningbo, Shandong, Shanghai, Shanghai Shi, Shenyang, Shenzhen, Shenzhen Shi, Shijiazhuang, Suzhou, Tianjin, Wuhan, Wuxi, Xi'an, Xuzhou, Yichang Shi, Yinchuan, Zhengzhou
Age
18 years and over
People
2,380 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT07441408 · EU 2025-522373-10-00
Phase 2Taking people
A Phase IIb Study to Evaluate AZD8965 in Participants With IPF.
Where
Beijing, Changchun, Changsha, Chengdu, Guangzhou, Lanzhou, Nanchang, Nanjing, Shanghai, Shenyang, Wuhan, Xuzhou, Zhengzhou
Age
40 years and over
People
359 worldwide
Run by
AstraZeneca
See details and how to joinNCT07652658
No phaseTaking people
Jin-shui Huan-xian Formula for Retarding the Decline of Pulmonary Function in IPF
Where
Zhengzhou
Age
40 years to 85 years
People
384
Run by
Henan University of Traditional Chinese Medicine
See details and how to joinNCT06914713
Phase 3Taking people
Study Evaluation Rentosertib (INS018_055) Administered Orally in Patients With Idiopathic Pulmonary Fibrosis (IPF)
Where
Anyang, Beijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Haikou, Hangzhou, Hefei, Hohhot, Jiaxing, Jinan, Kunming, Nanchang, Nanjing, Nanning, Nanyang, Ningbo, Shanghai, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Ürümqi, Wenzhou, Wuhan, Xiamen, Xi'an, Xuzhou, Yichang, Yuncheng, Zhengzhou
Age
40 years and over
People
320
Run by
InSilico Medicine Hong Kong Limited
See details and how to joinNCT07687459
No phaseTaking people
Daoyin Technique for Improving Exercise Endurance in IPF
Where
Beijing, Shenyang, Zhengzhou
Age
40 years to 85 years
People
236
Run by
Affiliated Hospital of Liaoning University of Traditional Chinese Medicine
See details and how to joinNCT07019714
No phaseTaking people
Inspiratory Flow Rate Capability in Pulmonary Fibrosis Patients
Where
Shanghai
Age
18 years to 80 years
People
60
Run by
Shanghai Pulmonary Hospital, Shanghai, China
See details and how to joinNCT07820254
Early phase 1Taking people
A Clinical Study to Evaluate Safety, Tolerability and Pharmacokinetics of SV001 in Chinese Healthy Adult Volunteers.
Where
Shanghai
Age
18 years to 45 years
People
53
Run by
Shanghai Synvida Biotechnology Co.,Ltd.
See details and how to joinNCT06267183
Phase 3Not yet taking people in China
A Phase 3 Study of Efficacy and Safety of AK3280 in Patients With Idiopathic Pulmonary Fibrosis
Where
Beijing
Age
40 years and over
People
263
Run by
Shanghai Ark Biopharmaceutical Co., Ltd.
See details and how to joinNCT07719023
No phaseTaking people
A Prospective, Multi-Center Registry Study of Progressive Pulmonary Fibrosis (PPF) in China (PROFINA)
Where
Beijing
People
600
Run by
Zuojun Xu
See details and how to joinNCT07683728
Phase 2Taking people
Phase II Clinical Study of BC006 in Patients With Idiopathic Pulmonary Fibrosis
Where
Shanghai
Age
40 years and over
People
96
Run by
Dragonboat Biopharmaceutical Company Limited
See details and how to joinNCT07447102
Phase 2Taking people
A Study to Explore the Therapeutic Effect of HEC585 on Delaying Forced Vital Capacity (FVC) Decline and Tolerance in Progressive Fibrosing Interstitial Lung Disease (PF-ILD) Patients
Where
Beijing
Age
18 years and over
People
110
Run by
Sunshine Lake Pharma Co., Ltd.
See details and how to joinNCT05139719
Phase 3Taking people
Confirmatory Clinical Study of HEC585 Tablets in Patients With IPF
Where
Beijing
Age
40 years to 80 years
People
472
Run by
Sunshine Lake Pharma Co., Ltd.
See details and how to joinNCT07082842
Phase 1Not yet taking people in China
Safety and Efficacy of Nebulized 3D-cultured Human Placental Mesenchymal Stem Cell-derived Extracellular Vesicles (hPMSC-EVs) for Idiopathic Pulmonary Fibrosis
Where
Beijing
Age
18 years to 75 years
People
9
Run by
Huan Ye
See details and how to joinNCT07515066
Phase 3Taking people
A Adaptive Design Clinical Trial to Evaluate the Efficacy and Safety of TDI01 Suspension in the Treatment of Idiopathic Pulmonary Fibrosis (IPF)
Where
Beijing
Age
40 years to 80 years
People
508
Run by
Beijing Tide Pharmaceutical Co., Ltd
See details and how to joinNCT07464912
Phase 2Taking people
A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of SV001 in Patients With Idiopathic Pulmonary Fibrosis
Where
Chengdu, Guangzhou, Hangzhou, Nanchang, Nanjing, Neimeng, Shanghai, Tianjin, Xuzhou, Zhengzhou
Age
40 years and over
People
48
Run by
Shanghai Synvida Biotechnology Co.,Ltd.
See details and how to joinNCT07121413
Early phase 1Not yet taking people in China
Treatment of Idiopathic Pulmonary Fibrosis (IPF) by REGEND007 Cell Therapy
Where
Yiwu
Age
40 years to 80 years
People
12
Run by
Regend Therapeutics
See details and how to joinNCT07359963
No phaseNot yet taking people in China
Disease-syndrome Characteristics of IPF
Where
Zhengzhou
Age
18 years and over
People
2,864
Run by
Henan University of Traditional Chinese Medicine
See details and how to joinNCT07178392
No phaseNot yet taking people in China
Idiopathic Pulmonary Fibrosis Cohort of TCM
Where
Zhengzhou
Age
40 years and over
People
1,000
Run by
Henan University of Traditional Chinese Medicine
See details and how to joinNCT07162870
Phase 2Not yet taking people in China
Menstrual Blood-Derived Mesenchymal Stem Cell Injection (SC01009) in the Treatment of Idiopathic Pulmonary Fibrosis
Where
Beijing, Changchun, Changsha, Chengdu, Guangzhou, Hebei, Nanjing, Shanghai, Shenzhen, Tianjin, Wuhan, Xi’an, Xuzhou, Yinchuan, Zhengzhou
Age
18 years to 80 years
People
66
Run by
Ruijin Hospital
See details and how to joinNCT07131150
No phaseNot yet taking people in China
Perioperative Risk Factors Related to the Prognosis of Lung Transplantation: A Retrospective Study
Where
Hangzhou
Age
18 years and over
People
250
Run by
Zhejiang University
See details and how to joinNCT06922916
No phaseTaking people
Application of Transbronchial Cryobiopsy in the Diagnosis of Progressive Pulmonary Fibrosis
Where
Beijing
Age
18 years to 80 years
People
100
Run by
China-Japan Friendship Hospital
See details and how to joinNCT06251687
Phase 2/3Taking people
SC1011 Twice Daily vs Placebo in Patients Diagnosed With Idiopathic Pulmonary Fibrosis (IPF)
Where
Beijing
Age
40 years to 80 years
People
210
Run by
Guangzhou JOYO Pharma Co., Ltd
See details and how to joinNCT06125327
No phaseTaking people
A Multicenter Prospective Study of Risk Factors in Progressive Pulmonary Fibrosis
Where
Jinan
Age
18 years to 80 years
People
610
Run by
Qianfoshan Hospital
See details and how to joinNCT05895409